Takeda Offers $2.4bn No-Fault Settlement Of Actos Suits
This article was originally published in PharmAsia News
Following rumors a few weeks ago, Takeda has now formally agreed to settle most of the U.S. product lawsuits relating to its diabetes drug Actos, for a total of around $2.4 billion but with no admission of liability, in a move that will see the firm post a full-year loss.
You may also be interested in...
GSK and Sanofi will continue to defend against all claims alleging ranitidine increased risk of cancer. Four Rx generic firms reach settlements in first case scheduled for trial. Former US OTC Zantac marketers GSK and Sanofi, which markets the Zantac OTC brand in the US, along with former Rx brand marketer Pfizer could pay $1bn to $2bn each in potential settlements, analyst predicts.
GlaxoSmithKline will continue to defend itself against all claims alleging ranitidine increased the risk of cancer. Four generic firms reach settlements in the first case that had been scheduled for trial. GSK, Sanofi and Pfizer could pay $1bn-$2bn each in potential settlements, an analyst predicts.
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.